Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11294117 | PMC |
| http://dx.doi.org/10.3389/fendo.2024.1447314 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of a fractional order epidemiological model for tuberculosis transmission with vaccination and reinfection.
Sci Rep
November 2024
Department of Mathematics and Statistics, Texas Tech University, Lubbock, TX, 79409, USA.
This study has been carried out using a novel mathematical model on the dynamics of tuberculosis (TB) transmission considering vaccination, endogenous re-activation of the dormant infection, and exogenous re-infection. We can comprehend the behavior of TB under the influence of vaccination from this article. We compute the basic reproduction number ( ) as well as the vaccination reproduction number ( ) using the next-generation matrix (NGM) approach.
View Article and Find Full Text PDFLocal re-activation of osteoclast differentiation as a novel therapeutic strategy for osteonecrosis of the jaw.
Front Endocrinol (Lausanne)
August 2024
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Reuniens thalamus recruits recurrent excitation in medial prefrontal cortex.
bioRxiv
June 2024
Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
Unlabelled: Medial prefrontal cortex (mPFC) and hippocampus are critical for memory retrieval, decision making and emotional regulation. While ventral CA1 (vCA1) shows direct and reciprocal connections with mPFC, dorsal CA1 (dCA1) forms indirect pathways to mPFC, notably via the thalamic Reuniens nucleus (Re). Neuroanatomical tracing has documented structural connectivity of this indirect pathway through Re however, its functional operation is largely unexplored.
View Article and Find Full Text PDFCombination p53 activation and BCL-x/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Leukemia
June 2024
Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
Article Synopsis
- TP53 mutations are rare in acute lymphoblastic leukemia (ALL), making the MDM2 antagonist idasanutlin a promising treatment option for most ALL cases.
- Combining idasanutlin with the BCL-x/BCL-2 inhibitor navitoclax has shown significant antileukemic effects in laboratory models, leading to a synergistic reduction in leukemia cell viability.
- These findings highlight the potential of using both drugs together in treating high-risk and relapsed ALL patients, with the combination demonstrating effectiveness at safe drug concentration levels seen in clinical trials.
An integrated, cross-regulation pathway model involving activating/adaptive and feed-forward/feed-back loops for directed oscillatory cAMP signal-relay/response during the development of .
Front Cell Dev Biol
January 2024
Laboratory of Cellular and Developmental Biology, National Institute of Diabetes and Digestive and Kidney Diseases, The National Institutes of Health, Bethesda, MD, United States.
Self-organized and excitable signaling activities play important roles in a wide range of cellular functions in eukaryotic and prokaryotic cells. Cells require signaling networks to communicate amongst themselves, but also for response to environmental cues. Such signals involve complex spatial and temporal loops that may propagate as oscillations or waves.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!